HOME Top Market Reports Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecasts to 2021

Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecasts to 2021

By: marketsandmarkets.com
Publishing Date: June 2016
Report Code: BT 4378

 

  Speak to Analyst Enquiry Before Buying  
purchase report
download pdf  request for customisation


The global vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016, at a CAGR of 10.5%. The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.

On the basis of product type, the vaccine adjuvants market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and others. The particulate adjuvants segment is expected to account for the largest share of the global market in 2016. The adjuvant emulsions segment, on the other hand, is projected to grow at the highest CAGR during the forecast period. This market is mainly driven by factors such as rising prevalence of diseases such as allergy, cancer, and HIV/AIDS; growing demand for advanced treatment options, and development of improved vaccine immunization.

On the basis of route of administration, the market is segmented into oral, subcutaneous, intranasal, intramuscular, intradermal, and others. The intramuscular segment is expected to account for the largest share of the global vaccine adjuvants market in 2016. Factors such as the rapidly growing geriatric population and vaccines for improved immunization are propelling the growth of this market. Rise in collaborations and acquisitions by private organizations and increased funding by government bodies for research and development are also expected to drive market growth.

On the basis of disease type, the vaccine adjuvants market is segmented into infectious diseases, cancer, and others. The infectious diseases segment is expected to account for the largest share of the global market in 2016. Factors such as high prevalence of infectious diseases, government & company initiatives, and high prevalence of cancer cases are expected to drive market growth in the coming years.

On the basis of applications, the market is segmented into research and commercial applications. The research applications segment is expected to account for the largest share of the market during the forecast period. Growth in this segment is driven by factors such as ongoing research projects on new adjuvants, increasing initiatives by government bodies and companies, growing usage of many vaccine adjuvants commercially, and increasing incidences of zoonotic diseases.

On the basis of application categories, the market is segmented into human vaccine adjuvants and veterinary vaccine adjuvants. The human vaccine adjuvants segment is expected to account for the largest share of the global market in 2016 and is also expected to grow at the higher CAGR. The large share of this segment can primarily be attributed to factors such as increasing initiatives by companies.

Geographically, the vaccine adjuvants market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is projected to grow at the highest CAGR during the forecast period. Growth in the North American segment is primarily driven by the increasing geriatric population and rising incidences of diseases in the North American countries.

The major players in the vaccine adjuvants market are Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MPV Technologies (U.S.), and OZ Biosciences (France).

Target Audience for this Report:

  • Vaccine adjuvants manufacturers and suppliers
  • Academic research institutes
  • Biopharmaceutical and biotechnology companies
  • Research and development (R&D) companies
  • Business research and consulting service providers
  • Medical research laboratories
  • Academic medical centers and universities

Value Addition for the Buyer:

This report aims to provide insights into the global vaccine adjuvants market. It provides valuable information on the product type, route of administration, disease type, applications, and application categories in the market. Furthermore, the information for these segments, by region, is also presented in this report. Leading players in the market are profiled to study their product offerings and understand the strategies undertaken by them to be competitive in this market.

The above-mentioned information would benefit buyers by helping them understand the market dynamics. In addition, the forecasts provided in the report will enable firms to understand the trends in this market and better position themselves to capitalize the growth opportunities.

To know about the assumptions considered for the study, download the pdf brochure

Scope of the Report:

This report categorizes the vaccine adjuvants market into the following segments:

Vaccine Adjuvants Market, by Product Type

  • Pathogen Components
  • Adjuvant Emulsions
  • Particulate Adjuvants
  • Combination Adjuvants
  • Others

Vaccine Adjuvants Market, by Route of Administration 

  • Oral
  • Subcutaneous
  • Intranasal
  • Intramuscular
  • Intradermal
  • Others

Vaccine Adjuvants Market, by Disease Type

  • Infectious Diseases
  • Cancer
  • Others

Vaccine Adjuvants Market, by Application

  • Research Applications
  • Commercial Applications

Vaccine Adjuvants Market, by Application Category

  • Human Vaccine Adjuvants
  • Veterinary Vaccine Adjuvants

Customization Options:

  • Company Information: Detailed company profiles of five or more market players
  • Opportunities Assessment: A detailed report underlining the various growth opportunities presented in the market

Table of Contents

1 Introduction (Page No. - 14)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Market Segmentation
           1.3.2 Markets Covered
           1.3.3 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Market Stakeholders

2 Research Methodology (Page No. - 18)
    2.1 Key Indicators
           2.1.1 Introduction
           2.1.2 Macroindicators
                    2.1.2.1 Rapid Growth of Aging Population
                    2.1.2.2 Incidence and Prevalence of Cancer
                    2.1.2.3 Burden of Infectious Diseases
                    2.1.2.4 Healthcare Expenditure Patterns
    2.2 Market Size Estimation
    2.3 Market Breakdown and Data Triangulation
    2.4 Key Data From Secondary Sources
    2.5 Key Data From Primary Sources
    2.6 Key Industry Insights
    2.7 Assumptions for the Study

3 Executive Summary (Page No. - 32)
    3.1 Introduction
    3.2 Current Scenario
    3.3 Future Outlook
    3.4 Conclusion

4 Premium Insights (Page No. - 38)
    4.1 Market Overview
    4.2 Market, By Application
    4.3 Geographical Snapshot of the Market
    4.4 Geographic Analysis: Market,  By Application Category
    4.5 Geographic Analysis: Market, By Disease Type
    4.6 Lifecycle Analysis, By Region, 2015

5 Market Overview (Page No. - 44)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Increasing Use of Adjuvants in Vaccine
                    5.2.1.2 High Prevalence of Infectious and Zoonotic Diseases
                    5.2.1.3 Increase in Livestock and Instances of Diseases
                    5.2.1.4 Increasing Focus on Immunization Programs From Various Government Bodies
                    5.2.1.5 Technological Advancements in Aluminum Hydroxide-Based Adjuvants
                    5.2.1.6 Increasing Focus and Support on the Discovery and Development of Vaccine Adjuvants
                    5.2.1.7 Increasing Geriatric Population
           5.2.2 Restraints
                    5.2.2.1 High Cost of Adjuvant Research
                    5.2.2.2 Stringent Regulatory Environment and Time-Consuming Approvals
           5.2.3 Opportunities
                    5.2.3.1 Combination Adjuvants
                    5.2.3.2 Pandemic Diseases
           5.2.4 Challenges
                    5.2.4.1 Identification of Adjuvants
           5.2.5 Trends
                    5.2.5.1 Collaborations
    5.3 Key Pipeline Products
    5.4 Regulatory Landscape
           5.4.1 North America
           5.4.2 Europe
                    5.4.2.1 Manufacturing Specifications
                    5.4.2.2 Routine Testing
                    5.4.2.3 Stability
           5.4.3 Asia
           5.4.4 RoW

6 Global Vaccine Adjuvants Market, By Product Type (Page No. - 58)
    6.1 Introduction
    6.2 Particulate Adjuvants
    6.3 Adjuvant Emulsions
    6.4 Pathogen Components
    6.5 Combination Adjuvants
    6.6 Others

7 Global Vaccine Adjuvants Market, By Route of Administration (Page No. - 72)
    7.1 Introduction
    7.2 Intramuscular Route
    7.3 Subcutaneous Route
    7.4 Intranasal Route
    7.5 Oral Route
    7.6 Intradermal Route
    7.7 Others

8 Global Vaccine Adjuvant Market, By Disease Type (Page No. - 81)
    8.1 Introduction
    8.2 Infectious Diseases
    8.3 Cancer
    8.4 Others

9 Global Vaccine Adjuvants Market, By Application (Page No. - 88)
    9.1 Introduction
    9.2 Research Application
    9.3 Commercial Application

10 Global Vaccine Adjuvants Market, By Application Category (Page No. - 93)
     10.1 Introduction
     10.2 Human Vaccine Adjuvants
     10.3 Veterinary Vaccine Adjuvants

11 Global Vaccine Adjuvants Market, By Region (Page No. - 98)
     11.1 Introduction
     11.2 North America
             11.2.1 U.S.
             11.2.2 Canada
     11.3 Europe
             11.3.1 Germany
             11.3.2 U.K.
             11.3.3 France
             11.3.4 Rest of Europe
     11.4 Asia
             11.4.1 China
             11.4.2 India
             11.4.3 Rest of Asia
     11.5 Rest of the World

12 Competitive Landscape (Page No. - 125)
     12.1 Overview
     12.2 Market Share Analysis
     12.3 Competitive Situation and Trends
             12.3.1 Agreements & Collaborations
             12.3.2 Acquisitions
             12.3.3 Expansions
             12.3.4 Others

13 Company Profile (Page No. - 130)
(Overview, Financial*, Products & Services, Strategy, and Developments)
     13.1 Introduction
     13.2 Brenntag Biosector A/S (A Subsidiary of Brenntag AG)
     13.3 Seppic (A Subsidiary of Air Liquide Group)
     13.4 CSL Limited
     13.5 Agenus, Inc.
     13.6 Novavax, Inc.
     13.7 Invivogen
     13.8 SPI Pharma, Inc. (A Subsidiary of Associated British Foods PLC.)
     13.9 Avanti Polar Lipids, Inc.
     13.10 MPV Technologies, Inc.
     13.11 OZ Biosciences

*Details Might Not Be Captured in Case of Unlisted Companies.

14 Appendix (Page No. - 148)
     14.1 Insights of Industry Experts
     14.2 Discussion Guide
     14.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
     14.4 Available Customizations
     14.5 Introducing RT: Real-Time Market Intelligence
     14.6 Related Reports


List of Tables (90 Tables)

Table 1 Increasing Use of Adjuvants in Vaccine-Preventable Diseases Drives the Market Growth
Table 2 High Cost of Adjuvant Research Restraints the Market Growth
Table 3 Combined Adjuvants and Pandemic Diseases Offer Growth Opportunities for Market Players
Table 4 Identification of Adjuvants Challenges the Growth of This Market
Table 5 Collaborations Offer Growth Trends for Market Players
Table 6 Fda Approved Vaccine Adjuvants
Table 7 Licensed Vaccines Containing Adjuvants
Table 8 Examples of Vaccine Adjuvants in Clinical Trials
Table 9 Vaccine Adjuvants Market Size, By Product Type, 2014–2021
Table 10 List of Particulate Adjuvants Approved for Human Use (2015)
Table 11 Particulate Adjuvants Market Size, By Region, 2014–2021(USD Million)
Table 12 North America Particulate Adjuvants Market Size, By Country, 2014–2021(USD Million)
Table 13 Europe Particulate Adjuvants Market Size, By Country, 2014–2021(USD Million)
Table 14 Asia Particulate Adjuvants Market Size, By Country, 2014–2021(USD Million)
Table 15 List of Adjuvant Emulsions Approved for Human Use (2015)
Table 16 Adjuvants Emulsion Market Size, By Region, 2014–2021(USD Million)
Table 17 North America Adjuvant Emulsions Market Size, By Country, 2014–2021(USD Million)
Table 18 Europe Adjuvant Emulsions Market Size, By Country, 2014–2021(USD Million)
Table 19 Asia Adjuvant Emulsions Market Size, By Country, 2014–2021(USD Million)
Table 20 Pathogen Components and Its Description
Table 21 Pathogen Components Market Size, By Region, 2014–2021(USD Million)
Table 22 North America Pathogen Components Market Size, By Country, 2014–2021(USD Million)
Table 23 Europe Pathogen Components Market Size, By Country, 2014–2021(USD Million)
Table 24 Asia Pathogen Components Market Size, By Country, 2014–2021(USD Million)
Table 25 List of Combination Adjuvant Approved for Human Use (2015)
Table 26 Combination Adjuvants Market Size, By Region, 2014–2021(USD Million)
Table 27 North America Combination Adjuvants Market Size, By Country, 2014–2021(USD Million)
Table 28 Europe Combination Adjuvants Market Size, By Country, 2014–2021(USD Million)
Table 29 Asia Combination Adjuvants Market Size, By Country, 2014–2021(USD Million)
Table 30 Other Adjuvants and Its Description
Table 31 Others Adjuvants Market Size, By Region, 2014–2021(USD Million)
Table 32 North America Others Vaccine Adjuvants Market Size, By Country, 2014–2021(USD Million)
Table 33 Europe Others Vaccine Adjuvants Market Size, By Country, 2014–2021(USD Million)
Table 34 Asia Others Vaccine Adjuvants Market Size, By Country, 2014–2021(USD Million)
Table 35 Vaccine Adjuvants Market Size, By Route of Administration, 2014–2021(USD Million)
Table 36 Intramuscular Route of Administration Market Size, By Region, 2014–2021(USD Million)
Table 37 Subcutaneous Route of Administration Market Size, By Region, 2014–2021(USD Million)
Table 38 Intranasal Route of Administration Market Size, By Region, 2014–2021(USD Million)
Table 39 Oral Route of Administration Market Size, By Region, 2014–2021(USD Million)
Table 40 Intradermal Route of Administration Market Size, By Region, 2014–2021(USD Million)
Table 41 Others Route of Administration Market Size, By Region, 2014–2021(USD Million)
Table 42 Market Size, By Disease Type, 2014–2021(USD Million)
Table 43 New Cases of Diseases (2014)
Table 44 Infectious Diseases Vaccine Adjuvants Market Size, By Region, 2014–2021(USD Million)
Table 45 Cancer Disease Vaccine Adjuvants Market Size, By Region, 2014–2021(USD Million)
Table 46 Others Vaccine Adjuvants Market Size, By Region, 2014–2021(USD Million)
Table 47 Vaccine Adjuvants Market Size, By Application, 2014–2021(USD Million)
Table 48 Vaccine Adjuvants Market, By Research Application, By Region, 2014–2021(USD Million)
Table 49 Vaccine Adjuvants Market, By Commercial Application, By Region, 2014–2021(USD Million)
Table 50 Market Size, By Application Category, 2014–2021 (USD Million)
Table 51 List of Adjuvants Approved for Human Use By Fda
Table 52 Human Vaccine Adjuvants Market Size, By Region, 2014–2021 (USD Million)
Table 53 Veterinary Vaccine Adjuvants Market Size, By Region, 2014–2021(USD Million)
Table 54 Market Size, By Region, 2014–2021 (USD Million)
Table 55 North America: Market Size, By Country, 2014–2021 (USD Million)
Table 56 Europe: Market Size, By Country, 2014–2021 (USD Million)
Table 57 Asia: Market Size, By Country, 2014–2021 (USD Million)
Table 58 North America: Market Size, By Product Type, 2014–2021 (USD Million)
Table 59 North America: Market Size, By Route of Administration, 2014–2021 (USD Million)
Table 60 North America: Market Size, By Disease Type, 2014–2021(USD Million)
Table 61 North America: Market Size, By Application, 2014–2021(USD Million)
Table 62 North America: Market Size, By Application Category, 2014–2021(USD Million)
Table 63 U.S.: Market Size, By Product Type, 2014–2021, (USD Million)
Table 64 Canada: Market Size, By Product Type, 2014–2021(USD Million)
Table 65 Europe: Market Size, By Product Type, 2014–2021 (USD Million)
Table 66 Europe: Market Size, By Route of Administration, 2014–2021 (USD Million)
Table 67 Europe: Market Size, By Disease Type, 2014–2021(USD Million)
Table 68 Europe: Market Size, By Application, 2014–2021(USD Million)
Table 69 Europe: Market Size, By Application Category, 2014–2021 (USD Million)
Table 70 Germany: Market Size, By Product Type, 2014–2021 (USD Million)
Table 71 U.K.: Market Size, By Product Type, 2014–2021 (USD Million)
Table 72 France: Market Size, By Product Type, 2014–2021 (USD Million)
Table 73 Rest of Europe: Market Size, By Product Type, 2014–2021 (USD Million)
Table 74 Asia: Market Size, By Product Type, 2014–2021 (USD Million)
Table 75 Asia: Market Size, By Route of Administration, 2014–2021 (USD Million)
Table 76 Asia: Market Size, By Disease Type, 2014–2021(USD Million)
Table 77 Asia: Market Size, By Application, 2014–2021(USD Million)
Table 78 Asia: Market Size, By Application Category, 2014–2021(USD Million)
Table 79 China: Market Size, By Product Type, 2014–2021 (USD Million)
Table 80 India: Market Size, By Product Type, 2014–2021 (USD Million)
Table 81 Rest of Asia:Market Size, By Product Type, 2014–2021 (USD Million)
Table 82 Rest of the World: Market Size, By Product Type, 2014–2021 (USD Million)
Table 83 Rest of the World: Market Size, By Route of Administration, 2014–2021 (USD Million)
Table 84 Rest of the World: Market Size, By Disease Type, 2014–2021(USD Million)
Table 85 Rest of the World: Market Size, By Application, 2014–2021(USD Million)
Table 86 Rest of the World: Market Size, By Application Category, 2014–2021(USD Million)
Table 87 Agreements & Collaborations, 2015
Table 88 Acquisitions, 2015–2016
Table 89 Expansions, 2014
Table 90 Others, 2014–2015


List of Figures (42 Figures)

Figure 1 Research Design
Figure 2 Increase in Aging Population, By Country (2010 vs 2015)
Figure 3 Percentage Increase in Aging Population, By Region (1980–2010 vs 2010–2040)
Figure 4 Global Burden of Cancer, By Region (2005–2030)
Figure 5 Number of New Cancer Cases By Country
Figure 6 Healthcare Expenditure Across Major Countries, 2000 vs 2012
Figure 7 Healthcare Spending Matrix, By Country (2013)
Figure 8 Market Size Estimation: Top-Down Approach
Figure 9 Market Size Estimation: Bottom-Up Approach
Figure 10 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 11 Data Triangulation Methodology
Figure 12 Vaccine Adjuvants Market Size, By Product Type, 2016 vs 2021 (USD Million)
Figure 13 Global Vaccine Adjuvants Market Size, By Route of Administration, 2016 vs 2021 (USD Million)
Figure 14 Global Vaccine Adjuvants Market Size, By Disease Type, 2016 vs 2021 (USD Million)
Figure 15 Global Vaccine Adjuvants Market Size, By Application, 2016 vs 2021 (USD Million)
Figure 16 Global Vaccine Adjuvants Market Size, By Application Category, 2016 vs 2021 (USD Million)
Figure 17 Global Vaccine Adjuvants Market, By Region, 2016 (USD Million)
Figure 18 The Vaccine Adjuvants Market is Expected to Showcase High Growth Opportunities During the Forecast Period
Figure 19 The Research Application Segment is Expected to Account for the Largest Market Share in 2016
Figure 20 Asian Countries are Expected to Witness the Highest Growth Rate During the Forecast Period
Figure 21 The Human Vaccine Adjuvants Segment is Expected to Grow at the Highest CAGR During the Forecast Period
Figure 22 The Infectious Disease Segment Will Continue to Dominate the Market in 2021
Figure 23 Asia is Expected to Witness the Highest Growth Rate in the Vaccine Adjuvants Market During the Forecast Period
Figure 24 The Particulate Adjuvants Segment is the Largest Segment of the Vaccine Adjuvants Market From 2016 to 2021
Figure 25 The Intranasal Route of Administration Segment is Expected to Grow at the Highest CAGR During the Forecast Period From 2016 to 2021
Figure 26 The Cancer Disease Type Segment is Projected to Grow at the Highest CAGR During the Forecast Period
Figure 27 Cancer Incidence, By Region, 2012–2020
Figure 28 The Research Application Segment is the Largest in the Vaccine Adjuvants Market From 2016 to 2021
Figure 29 Human Vaccine Adjuvants Accounts for the Largest Share in Vaccine Adjuvant Market, By Application Category, in 2016
Figure 30 Asia is Expected to Witness the Highest Growth in the Vaccine Adjuvants Market During the Forecast Period
Figure 31 North America: Vaccine Adjuvants Market Snapshot
Figure 32 European Vaccine Adjuvants Market Snapshot
Figure 33 Asia: Vaccine Adjuvants Market Snapshot
Figure 34 Agreements & Collaborations Was the Key Growth Strategy for Market Players, 2013–2016
Figure 35 Global Vaccine Adjuvants Market Share Analysis, By Key Players, 2015
Figure 36 Battle for Market Share: Agreements & Collaborations Was the Key Strategy Adopted By Market Players
Figure 37 Product Benchmarking for Major Players
Figure 38 Company Snapshot: Brenntag AG
Figure 39 Company Snapshot: Air Liquide Group
Figure 40 Company Snapshot: CSL Limited
Figure 41 Company Snapshot: Agenus, Inc.
Figure 42 Company Snapshot: Novavax, Inc.

The global vaccine adjuvants market consists of human and veterinary adjuvants that are used to improve the efficacy of vaccines. This market is driven by several factors such as increasing government funding for research, high prevalence of diseases, expanding biotechnology and biopharmaceutical industries, and growing focus on prevention of diseases. The high growth potential in emerging markets has opened an array of opportunities for the market. However, the high cost of adjuvant-based research and proven safety of adjuvants are hampering the growth of the global market.

The vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016 at a CAGR of 10.5%. This market is segmented based on product type, route of administration, disease type, applications, and application category.

On the basis of product type, the market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and other adjuvants. The particulate adjuvants segment is expected to account for the largest share of the global vaccine adjuvants market in 2016. High prevalence of infectious diseases and increasing funding for adjuvant research will drive the growth of this market segment.

Based on route of administration, the vaccine adjuvants market includes oral route, subcutaneous route, intranasal route, intramuscular route, intradermal route, and other routes. The intramuscular segment is expected to account for the largest share of the global market in 2016. Rising geriatric population and vaccines for improved immunization are the key factors propelling the growth of this market.

Based on disease type, the vaccine adjuvants market comprises of infectious diseases, cancer, and other diseases. The infectious diseases segment is expected to account for the largest share of the global market in 2016. High prevalence of infectious diseases and cancer is expected to drive market growth in the coming years.

Based on applications, the vaccine adjuvants market is segmented into research applications and commercial applications. The research applications segment is expected to account for the largest share of the market during the forecast period. The large share of this segment can be attributed to factors such as ongoing research on new adjuvants, increasing initiatives by government bodies and companies, usage of many vaccine adjuvants commercially, increasing incidences of zoonotic diseases, and increase in the number of conferences and summits.

Based on application categories, the vaccine adjuvants market is segmented into human and veterinary adjuvants. The human vaccine adjuvants segment is expected to account for the largest share of the global market in 2016 and is expected to have a higher growth rate in the application category segment. The large share of this segment can be attributed to the increasing initiatives by companies, vaccine adjuvants discovery and development, and increase in the number of conferences and summits.

Vaccine Adjuvants Market

Based on geography, the global vaccine adjuvants market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). The market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is expected to witness the highest CAGR, with the growth in this market centered at China and India. Rising prevalence of infectious diseases, increasing government investments for vaccine research and development, rising number of conferences and symposiums, and high growth in the Indian biotechnology sector are the major factors driving the market in the Asian region.

The major players in the vaccine adjuvants market are Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MPV Technologies (U.S.), and OZ Biosciences (France).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports



Access reports on all high
growth Biotechnology Markets on KnowledgeStore
Request Demo